Vanguard Group
ONCT

Vanguard Group’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Vanguard Group’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-139,884
Closed -$185K – 4385
2024
Q3 		$185K Sell
139,884
-3,159
-2% -$15.3K ﹤0.01% 4150
2024
Q2 		$1.09M Hold
143,043
– – ﹤0.01% 3764
2024
Q1 		$1.29M Sell
143,043
-2
-0% -$18 ﹤0.01% 3729
2023
Q4 		$1.53M Hold
143,045
– – ﹤0.01% 3693
2023
Q3 		$858K Hold
143,045
– – ﹤0.01% 3890
2023
Q2 		$987K Sell
143,045
-162
-0.1% -$1.07K ﹤0.01% 3900
2023
Q1 		$2.25M Hold
143,207
– – ﹤0.01% 3630
2022
Q4 		$2.86M Buy
143,207
+46
+0% +$916 ﹤0.01% 3532
2022
Q3 		$2.55M Buy
143,161
+36,410
+34% +$781K ﹤0.01% 3647
2022
Q2 		$2.37M Sell
106,751
-9,525
-8% -$212K ﹤0.01% 3736
2022
Q1 		$3.23M Buy
116,276
+9,610
+9% +$350K ﹤0.01% 3739
2021
Q4 		$4.84M Buy
106,666
+635
+0.6% +$42.7K ﹤0.01% 3627
2021
Q3 		$8.84M Buy
106,031
+651
+0.6% +$53.9K ﹤0.01% 3315
2021
Q2 		$10M Buy
105,380
+17,279
+20% +$2.05M ﹤0.01% 3198
2021
Q1 		$14.7M Buy
88,101
+4,026
+5% +$532K ﹤0.01% 2944
2020
Q4 		$8.24M Buy
84,075
+70,160
+504% +$4.44M ﹤0.01% 3093
2020
Q3 		$473K Sell
13,915
-310
-2% -$15.2K ﹤0.01% 3830
2020
Q2 		$808K Sell
14,225
-17
-0.1% -$959 ﹤0.01% 3659
2020
Q1 		$834K Hold
14,242
– – ﹤0.01% 3543
2019
Q4 		$1.13M Buy
14,242
+8,238
+137% +$852K ﹤0.01% 3611
2019
Q3 		$601K Buy
6,004
+4,415
+278% +$452K ﹤0.01% 3775
2019
Q2 		$211K Buy
1,589
+239
+18% +$36.9K ﹤0.01% 3969
2019
Q1 		$227K Sell
1,350
-61
-4% -$9.1K ﹤0.01% 3900
2018
Q4 		$154K Sell
1,411
-1,928
-58% -$386K ﹤0.01% 3937
2018
Q3 		$734K Buy
3,339
+540
+19% +$1.3M ﹤0.01% 3785
2018
Q2 		$6M Buy
2,799
+818
+41% +$2.07M ﹤0.01% 3143
2018
Q1 		$4.92M Sell
1,981
-12
-0.6% -$26.7K ﹤0.01% 3161
2017
Q4 		$3.54M Buy
1,993
+937
+89% +$1.36M ﹤0.01% 3256
2017
Q3 		$1.22M Buy
1,056
+510
+93% +$459K ﹤0.01% 3540
2017
Q2 		$404K Sell
546
-46
-8% -$28.2K ﹤0.01% 3760
2017
Q1 		$402K Hold
592
– – ﹤0.01% 3788
2016
Q4 		$437K Sell
592
-46
-7% -$49.2K ﹤0.01% 3757
2016
Q3 		$700K Sell
638
-5
-0.8% -$4.36K ﹤0.01% 3673
2016
Q2 		$495K Hold
643
– – ﹤0.01% 3798
2016
Q1 		$451K Buy
643
+3
+0.5% +$2.6K ﹤0.01% 3811
2015
Q4 		$628K Hold
640
– – ﹤0.01% 3767
2015
Q3 		$681K Buy
640
+67
+12% +$97.9K ﹤0.01% 3752
2015
Q2 		$1.18M Buy
573
+9
+2% +$12.8K ﹤0.01% 3617
2015
Q1 		$533K Buy
564
+8
+1% +$7.95K ﹤0.01% 3813
2014
Q4 		$569K Buy
556
+9
+2% +$8.03K ﹤0.01% 3687
2014
Q3 		$565K Buy
547
+40
+8% +$59K ﹤0.01% 3682
2014
Q2 		$979K Sell
507
-19
-4% -$37.6K ﹤0.01% 3491
2014
Q1 		$1.13M Buy
526
+85
+19% +$212K ﹤0.01% 3416
2013
Q4 		$1.02M Sell
441
-219
-33% -$501K ﹤0.01% 3410
2013
Q3 		$1.86M Hold
660
– – ﹤0.01% 3163
2013
Q2 		$6.1M Buy
+660
New +$5.09M ﹤0.01% 2552

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Vanguard Group's ONCT Position: Q4 2024 in Review

Vanguard Group sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 139,884 shares — an estimated $185K sold.

Vanguard Group first reported a position in ONCT in Q2 2013 and held it in 46 quarters. The position peaked at $14.7M in Q1 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Vanguard Group reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Vanguard Group sold 139,884 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $185K.
  • Vanguard Group first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 46 quarters.
  • Vanguard Group's Oncternal Therapeutics, Inc. Common Stock position peaked at $14.7M in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.